Summit Therapeutics 株価情報 (NASDAQ: SMMT)

最新ニュース Summit Therapeutics (NASDAQ:SMMT) 株価情報

SUMMIT THERAPEUTICS INC

Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics Inc

Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) sees Q2 sales of $235.000 million-$243.000 million vs $243.71 million analyst estimate.

News

Guidance

BMBL

Bumble Sees Q2 Sales $235.000M-$243.000M vs $243.71M Est

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.36, a high estimate of $29.00, and a low estimate of $7.00. A decline of 17.71% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655260_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Myriad Genetics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Myriad Genetics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Key Indicators: Myriad Genetics's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.12% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MYGN

What Analysts Are Saying About Myriad Genetics Stock

In the preceding three months, 5 analysts have released ratings for Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $36.0, a high estimate of $45.00, and a low estimate of $27.00. Highlighting a 5.76% decrease, the current average has fallen from the previous average price target of $38.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655250_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$38.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Viridian Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Viridian Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Viridian Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Viridian Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRDN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Viridian Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Viridian Therapeutics</h2>
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
<h3>Unraveling the Financial Story of Viridian Therapeutics</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Viridian Therapeutics's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately 0.0% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -110729.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -15.92%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.53%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Viridian Therapeutics's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRDN

What 5 Analyst Ratings Have To Say About Viridian Therapeutics

Ratings for Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $99.9, a high estimate of $125.00, and a low estimate of $83.00. A 7.02% drop is evident in the current average compared to the previous average price target of $107.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655230_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Lear among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$123.00</td>
<td>-</td>
</tr>
<tr>
<td>Dan Levy</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Mark Delaney</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Chris McNally</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Joseph Spak</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$103.00</td>
<td>$99.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lear. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lear compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Lear's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Lear's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LEA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lear analyst ratings.</a>
<h2>Delving into Lear's Background</h2>
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns most of its revenue from the seating segment.
<h3>Breaking Down Lear's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3M period, Lear faced challenges, resulting in a decline of approximately -2.17% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Lear's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Lear's ROE excels beyond industry benchmarks, reaching 1.91%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Lear's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.61%, the company showcases efficient use of assets and strong financial health.
Debt Management: Lear's debt-to-equity ratio is below the industry average. With a ratio of 0.65, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Lear Stock

In the current session, the stock is trading at $622.93, after a 1.27% increase. Over the past month, argenx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) stock increased by 10.42%, and in the past year, by 62.84%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1746655222_0.png" alt="Past Year Chart" />

<h3>argenx P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
argenx has a better P/E ratio of 48.13 than the aggregate P/E ratio of 47.71 of the Biotechnology industry. Ideally, one might believe that argenx Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746655222_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

ARGX

A Look Into argenx Inc's Price Over Earnings

Throughout the last three months, 10 analysts have evaluated SanDisk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $61.9, with a high estimate of $84.00 and a low estimate of $39.00. Observing a downward trend, the current average is 4.28% lower than the prior average price target of $64.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1746655219_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive SanDisk. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Thomas O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Mehdi Hosseini</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Positive</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Thomas O'Malley</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$84.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$56.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to SanDisk. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SanDisk compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of SanDisk's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of SanDisk's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNDK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SanDisk analyst ratings.</a>
<h2>Unveiling the Story Behind SanDisk</h2>
SanDisk Corp is one of the five largest suppliers of NAND flash memory semiconductors globally. Sandisk is vertically integrated, producing substantially all of its flash chips at manufacturing sites across Japan via a joint-venture framework with Kioxia. Sandisk then repackages majority of its chips into SSDs for consumer electronics, external storage, or cloud storage. Sandisk was formerly a piece of Western Digital for nine years (after being acquired in 2016) and was spun off as an independent company in 2025.
<h3>Key Indicators: SanDisk's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, SanDisk showcased positive performance, achieving a revenue growth rate of 12.67% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: SanDisk's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): SanDisk's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.87%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.73%, the company showcases effective utilization of assets.
Debt Management: SanDisk's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SNDK

What Analysts Are Saying About SanDisk Stock

Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) has outperformed the market over the past 5 years by 19.04% on an annualized basis producing an average annual return of 33.42%. Currently, Cloudflare has a market capitalization of $42.31 billion. 
Buying $1000 In NET: If an investor had bought $1000 of NET stock 5 years ago, it would be worth $4,328.24 today based on a price of $122.10 for NET at the time of writing.
<h3>Cloudflare's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746655215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

MariMed (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $37.95 million which missed the analyst consensus estimate of $38.45 million by 1.29 percent. This is a 0.06 percent increase over sales of $37.93 million the same period last year.

Earnings

Earnings Misses

MRMD

MariMed Q1 Adj. EPS $(0.01), Inline, Sales $37.95M Miss $38.45M Estimate

MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.13 by 107.69 percent. This is a 114.29 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $161.62 million which missed the analyst consensus estimate of $180.52 million by 10.47 percent. This is a 12.38 percent decrease over sales of $184.44 million the same period last year.

MISTRAS Group Q1 Adj. EPS $(0.01) Misses $0.13 Estimate, Sales $161.62M Miss $180.52M Estimate

WIIM

CVNA

CVNA stock has given up its prior loss. Carvana shares were trading lower. The company reported Q1 financial results.

Allied Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AAUC#TSX">AAUC</a>) reported quarterly earnings of $0.14 per share. The company reported $346.41 million in sales this quarter. This is a 97.87 percent increase over sales of $175.07 million the same period last year.

TSX:AAUC

Allied Gold Q1 Adj. EPS $0.14, Sales $346.41M Up From $175.07M YoY

Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key details from the <a href="https://www.benzinga.com/pressreleases/25/05/b45269632/cleveland-cliffs-reports-first-quarter-2025-results">steel producer&#8217;s report</a>.
Q1 Earnings: Cleveland-Cliffs reported first-quarter revenue of $4.63 billion, missing analyst <a href="http://benzinga.com/quote/clf/earnings">estimates</a> of $4.64 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The steelmaker reported a first-quarter adjusted loss of 92 cents per share, missing analyst estimates for a loss of 75 cents per share. 
Between March and May, the company decided to fully or partially idle six facilities to optimize its footprint, reposition away from loss-making operations and release excess working capital. These actions are expected to result in savings of over $300 million annually. 
&#8220;The decision to fully or partially idle certain locations was not taken lightly,&#8221; the company said. 
Total steelmaking revenues&nbsp;included&nbsp;$1.4 billion to the infrastructure and manufacturing market, $1.3 billion to the automotive market, $1.2 billion to the distributors and converters market and&nbsp;$588 million to steel producers.
Steel product sales volumes totaled 4.1 million net tons&nbsp;in the first quarter, consisting of 41%&nbsp;hot-rolled,&nbsp;27%&nbsp;coated,&nbsp;15%&nbsp;cold-rolled,&nbsp;5%&nbsp;plate,&nbsp;3%&nbsp;stainless and electrical and&nbsp;9%&nbsp;other.
Cleveland-Cliffs ended the quarter with $3 billion in total liquidity. 
&#8220;Our&nbsp;first-quarter&nbsp;results were negatively impacted by underperforming non-core assets and the lagging effect of lower index prices in late 2024 and early 2025,&#8221; said Lourenco Goncalves, chairman, president and CEO of Cleveland-Cliffs.
&#8220;As a result, we are taking decisive action to streamline our operations and enhance efficiency. This will drive meaningful fixed cost savings and sharpen our focus on our core strength: supplying steel to the automotive industry.&#8221;
Outlook: Cleveland-Cliffs expects full-year 2025 steel unit cost reductions of approximately&nbsp;$50&nbsp;per net ton compared to the prior year. The company anticipates full-year capital expenditures of approximately $625 million, down from prior guidance of $700 million. 
Cleveland-Cliffs executives will hold a conference call at 8:30 a.m. Thursday morning to further discuss the quarter with investors and analysts. 
CLF Price Action: <a href="http://benzinga.com/quote/clf">Cleveland-Cliffs shares</a> were down 9.19% after-hours, trading at $7.71 at the time of publication Wednesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45268560/carvana-q1-earnings-revenue-eps-beat-estimates-as-vehicles-sales-jump-46-company-remains-on-track-for-significant-growth-in-fy25">Carvana Q1 Earnings: Revenue, EPS Beat Estimates As Vehicles Sales Jump 46%, Company Remains On Track For &#8216;Significant Growth&#8217; In FY25</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45268429/arm-holdings-stock-plunges-after-q4-results-heres-why">Arm Holdings Stock Plunges After Q4 Results: Here&#8217;s Why</a></li>
</ul>
Photo: saweang.w/Shutterstock.

Commodities

After-Hours Center

Movers

Cleveland-Cliffs Stock Falls On Q1 Earnings Miss, Steelmaker Idles 6 Facilities: 'Taking Decisive Action To Streamline Our Operations'

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

SDGR

Schrodinger Software revenue growth is expected to range from 10% to 15%; Drug discovery revenue is expected to range from $45 million to $50 million.

Verisk Analytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NASDAQ">VRSK</a>) has outperformed the market over the past 15 years by 5.68% on an annualized basis producing an average annual return of 16.77%. Currently, Verisk Analytics has a market capitalization of $43.47 billion. 
Buying $100 In VRSK: If an investor had bought $100 of VRSK stock 15 years ago, it would be worth $1,035.76 today based on a price of $309.90 for VRSK at the time of writing.
<h3>Verisk Analytics's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746654312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRSK

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) affirms FY2025 sales outlook from $50.00 million-$53.00 million to $50.00 million-$53.00 million vs $61.78 million estimate.

Myomo Affirms FY2025 Sales Guidance of $50.00M-$53.00M vs $61.78M Est

Energy Fuels (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 750 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $16.90 million which beat the analyst consensus estimate of $15.20 million by 11.17 percent. This is a 33.54 percent decrease over sales of $25.43 million the same period last year.

Earnings Beats

UUUU

Energy Fuels Q1 EPS $(0.13) Misses $(0.05) Estimate, Sales $16.90M Beat $15.20M Estimate

Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) sees Q2 sales of $9.000 million-$9.500 million vs $13.60 million analyst estimate.

Myomo Sees Q2 Sales $9.000M-$9.500M vs $13.60M Est

The board of directors of The Brink's Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCO#NYSE">BCO</a>) today declared a regular quarterly dividend of $0.255 cents per share on the company's common stock, an increase of 5%. The dividend is payable on June 2, 2025, to shareholders of record on May 19, 2025.&nbsp;&nbsp;

Dividends

Brink's Increases Quarterly Dividend From $0.24 To $0.255 Per Share

Schrodinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.75) by 14.67 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $59.55 million which beat the analyst consensus estimate of $54.65 million by 8.96 percent. This is a 62.72 percent increase over sales of $36.60 million the same period last year.

Schrodinger Q1 Adj. EPS $(0.64) Beats $(0.75) Estimate, Sales $59.55M Beat $54.65M Estimate

Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) affirms FY2025 sales outlook from $345.00 million-$355.00 million to $345.00 million-$355.00 million vs $350.97 million estimate.

EOLS

Evolus Affirms FY2025 Sales Guidance of $345.00M-$355.00M vs $350.97M Est

Press Releases

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Comments

Summit Therapeutics

ニュース

最新ニュース Summit Therapeutics (NASDAQ:SMMT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル